Sanofi's 4 Billion Drug Ignites Rally--But the Clock Is Ticking

Sanofi SNY just reminded investors that one blockbuster can still carry an entire pharma giant. The French drugmaker smashed earnings expectations last quarter as Dupixent, its eczema and asthma powerhouse, posted record sales of 4.16 billion. Earnings per share came in at 2.91, well ahead of the 2.65 analysts expected. The stock jumped as much as 5.2% in early Paris tradingan overdue rebound after an 8% slide this year that left Sanofi lagging rivals like Novartis and Roche. Management kept full-year guidance unchanged, signaling confidence that Dupixent's growth trajectory remains intact.

But the Dupixent era won't last forever. Patent protection ends in 2031, and Sanofi is racing to refill its pipeline before the cliff arrives. The drug is still expected to peak above 21 billion in annual revenuean extraordinary figure for a single therapybut CEO Paul Hudson knows the future depends on what comes next. His R&D push now includes over a dozen potential blockbusters in late-stage trials. Not all are landing as hoped: an experimental eczema drug underwhelmed investors last month, while another project with Regeneron, itepekimab, showed uneven results in COPD trials among former smokers. The stakes are rising as Sanofi tries to prove its innovation engine can extend the Dupixent legacy.

Beyond its core drugs, the quarter exposed a few weak spots. Vaccine sales fell 17% amid price pressure in Europe and waning US flu-shot demand, with CFO Francois-Xavier Roger blaming post-Covid fatigue and general skepticism toward vaccines. Currency swings also shaved roughly 4% off quarterly sales. Roger said the company remains in ongoing discussions with President Donald Trump's administration about ways to make medicines more affordabletalks that could trade price concessions for tariff relief. Analysts at Bloomberg Intelligence noted that Sanofi's near-term margin expansion looks limited through 2026, leaving execution on new therapies as the key catalyst investors will be watching next.